anmelden
SPI Healthcare
3.597,97
PKT
+5,14
PKT
+0,14
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Leider sind zu diesem Wert keine aktuellen Kursdaten verfügbar, die Stammdaten finden Sie im unteren Seitenbereich.
Analysen zu SPI Healthcare-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 11.12.12 | Tecan (N) buy | UBS AG | |
| 11.12.12 | Novartis halten | Norddeutsche Landesbank (Nord/LB) | |
| 11.12.12 | Novartis reduce | Vontobel Research | |
| 10.12.12 | Straumann kaufen | Die Actien-Börse | |
| 10.12.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 10.12.12 | Basilea Pharmaceutica hold | Vontobel Research | |
| 10.12.12 | Basilea Pharmaceutica buy | Sarasin Research | |
| 04.12.12 | Sonova overweight | Morgan Stanley | |
| 30.11.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 29.11.12 | Lonza hold | Vontobel Research | |
| 27.11.12 | Novartis kaufen | Hamburger Sparkasse AG (Haspa) | |
| 26.11.12 | Straumann hold | Vontobel Research | |
| 26.11.12 | Lonza hold | Vontobel Research | |
| 26.11.12 | Straumann neutral | Sarasin Research | |
| 23.11.12 | Sonova kaufen | Fuchsbriefe | |
| 22.11.12 | Basilea Pharmaceutica hold | Vontobel Research | |
| 21.11.12 | Novartis reduce | Vontobel Research | |
| 20.11.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 20.11.12 | Novartis buy | Sarasin Research | |
| 16.11.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 15.11.12 | Novartis buy | UBS AG | |
| 15.11.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 14.11.12 | Sonova neutral | UBS AG | |
| 14.11.12 | Sonova overweight | J.P. Morgan Cazenove | |
| 14.11.12 | Sonova underperform | Exane-BNP Paribas SA | |
| 14.11.12 | Sonova buy | Vontobel Research | |
| 13.11.12 | Sonova buy | Vontobel Research | |
| 13.11.12 | Sonova neutral | Sarasin Research | |
| 12.11.12 | Novartis outperform | Credit Suisse Group | |
| 12.11.12 | Sonova underperform | Exane-BNP Paribas SA | |
| 08.11.12 | Novartis reduce | Vontobel Research | |
| 08.11.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 07.11.12 | Sonova equal-weight | Morgan Stanley | |
| 07.11.12 | Novartis reduce | Vontobel Research | |
| 06.11.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 05.11.12 | Novartis neutral | Citigroup Corp. | |
| 06.11.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 01.11.12 | Straumann underperform | Exane-BNP Paribas SA | |
| 01.11.12 | Lonza hold | Vontobel Research | |
| 31.10.12 | Straumann neutral | Nomura |